Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.

Date publication

avril 2018

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr CLEMENT-DUCHENE Christelle , Pr FALCOZ Pierre-Emmanuel , Pr VIGNAUD Jean-Michel

Tous les auteurs :
Renaud S, Seitlinger J, Guerrera F, Reeb J, Beau-Faller M, Voegeli AC, Siat J, Clément-Duchêne C, Tiotiu A, Santelmo N, Costardi L, Ruffini E, Falcoz PE, Vignaud JM, Massard G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29362963

Résumé

The prognostic value of exon 19 and 21 EGFR mutations in stage IV non-small cell lung cancer (NSCLC) is well established.

Mots clés

Adenocarcinoma, genetics, Aged, Biomarkers, Tumor, genetics, Carcinoma, Non-Small-Cell Lung, genetics, ErbB Receptors, genetics, Exons, Female, Follow-Up Studies, Humans, Lung Neoplasms, genetics, Male, Mutation, Neoplasm Staging, Retrospective Studies, Survival Rate

Référence

Ann. Surg. Oncol.. 2018 Apr;25(4):1069-1078